Quantcast

Cordis Launching Two New Products at EuroPCR Congress

May 16, 2011

PARIS, May 16, 2011 /PRNewswire/ –

– Cordis Continues its History of Innovation With Two New Products:
EMPIRA(TM) and RADIALSOURCE(TM)

Cordis announced it has obtained CE mark for its EMPIRA(TM) and
EMPIRA(TM) NC RX PTCA* Dilatation Catheters for the treatment of coronary
artery disease. The EMPIRA(TM) systems are designed to enable interventional
cardiologists to open patients’ narrowed coronary arteries during angioplasty
and stenting procedures.

The EMPIRA(TM) family of PTCA dilatation catheters incorporates several
design and technology changes that have the potential to improve crossability
and recrossability, allowing a physician to reach even hard to treat lesions.
Both catheters utilise the next generation DURALYN(R) Flex balloon material
which is 50% more flexible than the DURALYN(R) balloon material used in the
current dilatation catheters[1]. EMPIRA(TM) will be made available in
selected sizes to a limited number of centres in Europe during the summer. A
full European commercial launch of EMPIRA(TM) is planned for Q4 2011.

“The EMPIRA(TM) family of PTCA dilatation catheters offers our most
advanced technology designed to treat challenging coronary artery disease,”
said Campbell Rogers, MD, Cordis Chief Scientific Officer, Global Head R&D.
“Cordis worked closely with our physician-customers and incorporated their
feedback into the design of these next generation devices. We believe the
unique design of the EMPIRA(TM) and EMPIRA(TM) NC PTCA Dilatation Catheters
will meet physicians’ needs and expand the array of high quality tools that
we offer to physicians to treat their patients with coronary artery disease.”

Cordis Radial Solutions – Integrated Solutions for Transradial Care

Cordis announces the launch in Europe of Radial Solutions, a complete
portfolio for transradial interventions. New to the portfolio is the Cordis
RADIALSOURCE(TM) Transradial Access Kit. RADIALSOURCE(TM) transradial sheaths
are designed to provide cardiologists with atraumatic and smooth access to
the radial artery during diagnostic and interventional procedures.

The RADIALSOURCE(TM) transradial sheath incorporates a new tapering
design in conjunction with a lubricious coating, offering the benefits of low
insertion force with a smooth atraumatic entry, while enabling stability
during procedure and ease of removal. Physicians will be offered a choice of
kit with a bare metal or a polymer-coated guidewire.

Cordis Radial Solutions encompass Cordis’ well known guiding and
diagnostic catheters with new specific radial shapes, transradial sheath
introducer, guidewires and professional education training.

“Radial access, with much fewer bleeding complications is becoming the
dominant access site in many countries. To meet this need Cordis has
introduced their ‘Radial Solutions portfolio’ which includes a comprehensive
range of dedicated radial sheaths and introducer options and have a
haemostasis device on the way. As a keen radial interventionalist it is great
to see Cordis taking such an active interest in radial access” said Douglas
G. Fraser, MB BChir MRCP DM, Interventional Cardiologist, Manchester Heart
Centre, Manchester Royal Infirmary UK.

About Cordis Corporation

For more than 50 years, Cordis Corporation, a Johnson & Johnson company,
has been a worldwide leader in the development and manufacture of
interventional vascular technology. Through the company’s innovation,
research and development, Cordis partners with interventional cardiologists
worldwide to treat millions of patients who suffer from vascular disease.

Reference:

Cordis data on file, 2010/2011.

*Percutaneous transluminal coronary angioplasty

SOURCE Cordis


Source: newswire



comments powered by Disqus